| 4.33 -0.3 (-6.48%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.58 | 1-year : | 6.52 |
| Resists | First : | 4.78 | Second : | 5.58 |
| Pivot price | 4.29  |
|||
| Supports | First : | 4 | Second : | 3.52 |
| MAs | MA(5) : | 4.46 |
MA(20) : | 4.14 |
| MA(100) : | 4.69 |
MA(250) : | 5.75 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.5 |
D(3) : | 74.9 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 8.59 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MYGN ] has closed below upper band by 46.4%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.68 - 4.7 | 4.7 - 4.72 |
| Low: | 4.16 - 4.19 | 4.19 - 4.21 |
| Close: | 4.29 - 4.33 | 4.33 - 4.37 |
Myriad Genetics, Inc. is a leading company specializing in genetic testing and precision medicine. The firm focuses on developing and marketing a wide array of genetic diagnostic solutions across both domestic U.S. and international landscapes. Their extensive diagnostic offerings cater to crucial medical fields, including oncology, women's health, and mental well-being. In cancer diagnostics, Myriad provides several sophisticated molecular tests. These include the MyRisk Hereditary Cancer Test, which uses DNA sequencing to evaluate an individual's susceptibility to inherited cancer types. The BRACAnalysis CDx functions as a vital companion diagnostic, leveraging DNA sequencing to inform treatment strategies for patients with metastatic breast, ovarian, pancreatic, or prostate cancers carrying specific deleterious BRCA gene variants. Another key oncology product, the MyChoice CDx, is a tumor-based assay designed to ascertain homologous recombination deficiency status in ovarian cancer patients. Myriad also offers prognostic tools like the Prolaris Prostate Cancer Prognostic Test and the EndoPredict Breast Cancer Prognostic Test, both employing RNA expression analysis to gauge the aggressiveness of prostate and breast cancers, respectively. Furthermore, they offer Precise Tumor, a comprehensive solution aimed at guiding personalized cancer treatment. For women's health and prenatal care, Myriad presents essential screening options. The Prequel Prenatal Screen is a non-invasive maternal blood test used to identify significant chromosomal abnormalities in a fetus. Prospective parents can also utilize the Foresight Carrier Screen to assess their risk of transmitting recessive genetic conditions to their children. Addressing mental health, Myriad offers the GeneSight Psychotropic Mental Health Medication Test. This DNA genotyping test assists healthcare providers in optimizing the selection of psychotropic medications for individuals suffering from conditions such as depression, anxiety, and ADHD. Myriad Genetics has also established strategic alliances, notably with Illumina, Inc. and Intermountain Precision Genomics, to enhance its provision of both germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Fri, 12 Jun 2026
Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan - Stock Titan
Fri, 12 Jun 2026
Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan - Stock Titan
Wed, 10 Jun 2026
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Tue, 09 Jun 2026
Insider Sell Alert: Rashmi Kumar Sells 15,000 Shares of Myriad G - GuruFocus
Tue, 09 Jun 2026
Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Tue, 09 Jun 2026
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 94 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 97.6 (%) |
| Shares Short | 8,330 (K) |
| Shares Short P.Month | 8,240 (K) |
| EPS | -4.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.56 |
| Profit Margin | -41.3 % |
| Operating Margin | -21.5 % |
| Return on Assets (ttm) | -7.7 % |
| Return on Equity (ttm) | -23.6 % |
| Qtrly Rev. Growth | -20.8 % |
| Gross Profit (p.s.) | 4.01 |
| Sales Per Share | 5.89 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -1.01 |
| PEG Ratio | 1.2 |
| Price to Book value | 1.21 |
| Price to Sales | 0.73 |
| Price to Cash Flow | -15.61 |
| Dividend | 1.75 |
| Forward Dividend | 0 |
| Dividend Yield | 40.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|